A Phase 1/2 Study of Ixazomib as a Replacement for Bortezomib or Carfilzomib for Multiple Myeloma (MM) Patients Recently Relapsed or Refractory to Their Last Combination Regimen Containing Either Bortezomib or Carfilzomib

Trial Profile

A Phase 1/2 Study of Ixazomib as a Replacement for Bortezomib or Carfilzomib for Multiple Myeloma (MM) Patients Recently Relapsed or Refractory to Their Last Combination Regimen Containing Either Bortezomib or Carfilzomib

Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 15 Mar 2018

At a glance

  • Drugs Ixazomib (Primary) ; Ascorbic acid; Bortezomib; Carfilzomib; Dexamethasone; Doxorubicin; Lenalidomide; Melphalan; Prednisolone
  • Indications Multiple myeloma
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Biomira USA
  • Most Recent Events

    • 01 Mar 2018 Status changed from recruiting to discontinued.
    • 06 Jun 2017 Results (n=40) presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
    • 27 Feb 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Dec 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top